← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 249개
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Larotrectinib Sulfate (Larotrectinib Sulfate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 60%임상시험 5상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

Pegenzileukin (Pegenzileukin)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 92.9%임상시험 5상태 RECRUITING
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
CGTBiologicYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 2

CD123 targeted CAR-NK cells (CD123 targeted CAR-NK cells)

Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 4상태 RECRUITING
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 ACTIVE
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
CGTBiologicstaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 3상태 RECRUITING
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib Hydrochloride (Defactinib Hydrochloride)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 3상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Selinexor, dexamethasone, ixazomib, pomalidomide (Selinexor, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Venetoclax, dexamethasone, ixazomib, pomalidomide (Venetoclax, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Actinium Ac 225-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 2

CAR-T infusion (CAR-T infusion)

Refractory Metastatic Colorectal Cancer · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 67%임상시험 2상태 ACTIVE
CGTBiologicstaleGyala TherapeuticsPhase 1

CD84-CART (CD84-CART)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
AntibodystaleEli LillyPhase 2

Cetuximab + Irinotecan (Cetuximab + Irinotecan)

Advanced Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
효능 ORR 2.081%임상시험 2상태 ACTIVE
CGTBiologicstaleCartesian TherapeuticsPhase 2

CAR-T (Chimeric Antigen Receptor T Cells, Chimeric Antigen Receptor T Cells (CAR-T))

Relapsed or Refractory Aggressive B-cell Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 67%임상시험 2상태 RECRUITING
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Indium In 111-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
ADCBiologicstaleMenarini GroupPhase 1

MEN1309 (MEN1309)

Metastatic Solid Tumors; Relapsed/Refractory Non-Hodgkin Lymphoma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
임상시험 2상태 DISCONTINUED

5 / 13 페이지

← 이전다음 →